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The immunologic landscape of tumors has been continuously unveiled, providing a new look at the interactions
between cancer cells and the immune system. Emerging tumor cells are constantly eliminated by the immune
system, but some cells establish a long-term equilibrium phase leading to tumor immunoediting and, eventually,
evasion. During this process, tumor cells tend to acquire more mutations. Bearing a high mutation burden
leads to a greater number of neoantigens with the potential to initiate an immune response. Although many
tumors evoke an immune response, tumor clearance by the immune system does not occur due to a suppressive
tumor microenvironment. The mechanisms by which tumors achieve the ability to evade immunologic control
vary. Understanding these differences is crucial for the improvement and application of new immune-based
therapies. Much effort has been placed in developing in silico algorithms to predict tumor immunogenicity
and to characterize the microenvironment via high-throughput sequencing and gene expression techniques.
Each sequencing source, transcriptomics, and genomics yields a distinct level of data, helping to elucidate the
tumor-based immune responses and guiding the fine-tuning of current and upcoming immune-based therapies.
In this review, we explore some of the immunological concepts behind the new immunotherapies and the
bioinformatic tools to study the immunological aspects of tumors, focusing on neoantigen determination and
microenvironment deconvolution. We further discuss the immune-based therapies already in clinical use, those
underway for future clinical application, the next steps in immunotherapy, and how the characterization of
the tumor immune contexture can impact therapies aiming to promote or unleash immune-based tumor
elimination.
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Considerations regarding tumor recognition by the
immune system
Tumor neoantigens are peptides aberrantly expressed by a
cell either because the original protein is not expected to be
expressed or because they are derived from mutations or
frameshifts in protein sequences. The first neoantigens described
in the 1960’s were derived from an oncogenic virus. Neo-
antigens were first thought to be products of the virus genome
itself or products of the cell alterations induced by the viral
infection (1). After this first characterization of neoantigen
presence, the question of whether these aberrant peptides
were able to trigger an immune response was raised. Dif-
ferent groups have shown antibody responses against neo-
antigens, while others have suggested an absence of these
responses (2,3), since a cytotoxic response against neoantigens
in a leukemia murine model was not observed. We now
know that leukemias are among the tumors with the lowest
mutation burdens (4).
Much research has been performed on neoantigens
derived from pathogens, and it has become clear that innate
and adaptive immune cells are prone to respond to patho-
gens because pathogen-derived epitopes are quite different
from hosts. Tumors, on the other hand, consist of trans-
formed cells that harbor self-antigens, with the exception
of neoantigens that arise as a consequence of tumor-specific
mutations (5). Another class of self-expressed proteins that
are aberrantly expressed by tumors and can be recognized by
the immune system are tumor-associated antigens (TAAs).
TAAs consist of tissue-restricted antigens, i.e., cancer/testis (CT)
or embryonic genes (carcinoembryonic [CEA]), expressed at an
immunoprivileged site such as the testis or only during
the embryo stage. Therefore, TAAs are not supposed to be
presented in the thymus by thymic epithelial cells during
T cell repertoire selection (6). This tumor neoantigen reper-
toire and the peptides derived from their degradation
could be described as near-self rather than non-self, except
for mutation-derived neoantigens, which represent new
peptide sequences derived from alterations in primary
peptide sequences. To be recognized by immune cells, the
potential neoantigen needs to be presented by the class I or
II major histocompatibility complex (MHC, called human
leukocyte antigen [HLA] in humans). Once presented byDOI: 10.6061/clinics/2018/e429s
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class I HLA on professional antigen-presenting cells (APCs) to
CD8+ T cells, these peptides can be recognized as non-self,
triggering an effector response by CD8+ T cells against cells
harboring the mutation. This is one of the mechanisms that
helps to prevent the tumor growth derived from transformed
cells (5,7).
This neoantigen recognition mechanism is one of the pillars
of the immunological surveillance of tumor cells concept and
was originally proposed in the 1970s by Burnet and Thomas
(cited by Corthay) (8), ascribing to immune cells the capacity
of recognizing and eliminating transformed cells by detecting
mutations in tumors through neoantigen recognition.
This model was further refined into a more complex picture
that includes not only the elimination phase of transformed
cells by immune surveillance mechanisms but also two addi-
tional steps in tumor-immune system interplay: equilibrium
and escape (7). This new model predicts that tumors can be
eliminated by immune surveillance and that cells resistant to
this process will go through an equilibrium phase, in which the
tumor suffers the immunoediting process, with the elimina-
tion of cells expressing the more immunogenic variants among
the tumor cell subclones. During the equilibrium phase, this
Darwinian process selects tumor variants that will ultimately
escape from immune pressure and cause the appearance of
clinically detected tumors (7). The role of the immune system
in cancer control was recognized in 2012 when evasion from
the immune system and tumor-promoting inflammation were
included in the hallmarks of cancer (9).
The immune responses against tumors follow common
paths of immune responses, and each step of the response
(antigen-presenting cell activation, antigen presentation, prim-
ing of T cells, homing to tumor site, immune escape) can
be addressed by different immunotherapeutic maneuvers
aiming to increase immune responses to tumors and avoid
immune-modulation by tumor microenvironment cells. The
steps of the immune response targeted by immunotherapies
are presented in Figure 1.
Bioinformatics in the genomics era
During the last 13 years, we have faced the rapid develop-
ment of next-generation sequencing (NGS) technologies and
applications (10), which has enabled the comprehensive
characterization of somatic mutations in a large number
of tumor samples. Since mutations in protein-coding genes
of cancer cells are a source of potential neoantigens to be
recognized by the immune system, the predictive selection of
novel somatic mutations through deep sequencing analyses
Figure 1 - Different levels of antitumoral immunotherapy intervention approaches. Dendritic cells and macrophages (as professional
antigen presenting cells [APCs]) are key players in the immune response against transformed cells. In the immunization process, APCs
capture, process and present neoantigens from tumor cells to T cells via class I and II HLA molecules. Cancer vaccines based on the
patient’s own peptides or aberrantly expressed proteins (TAAs) can be captured and presented by APCs. Chemotherapy and radio-
therapy also induce immune responses to tumor cells by killing tumor cells and exposing an array of tumor antigens. The priming of
T cells in the lymph node and the effector functions of these T cells within the tumor are frequently impaired due to immuno-
suppressive mechanisms developed by tumor cells or immune cells in the tumor microenvironment. Immune checkpoint blockade (ICB)
therapy is able to block the inhibitory signals from tumor or innate immune cells, allowing T cells to mount a cytotoxic response against
the tumor. Therefore, if the patient has many tumor-infiltrating T cells (TILs), the tumor can be extracted and the TILs can be activated,
expanded in vitro, and reinfused into the patient, leading to cytotoxic responses. Since most tumors lack sufficient TILs for adoptive cell
transfer protocols, and mutation loads are frequently too low to trigger an effective ICB therapy or vaccine, alternative approaches
must be developed. If the tumor cells express a membrane-specific target, chimeric antigen receptors (CARs) can be designed and
transgenically expressed in T cells. CAR T cells are capable of recognizing the antigen independently of HLA presentation and can
mount cytotoxic responses against tumor cells. Adapted from (103).
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of the coding exomes and whole genomes in various cancer
types has become an important strategy to identify putative
tumor antigens that can be applied to elicit a tumor-specific
response (11,12). Together with DNA sequencing, transcrip-
tome sequencing allows accessing the expression of neoantigens
and characterizing the tumor microenvironment, including
the immune populations and the modulatory networks that
may play a role in the cross-talk between tumor cells and
the immune system (13). In this sense, immunoinformatics
has emerged as an important research field that represents
tremendous promise in oncology.
Immunogenic tumors
Tumor immunogenicity is directly influenced by the muta-
tion burden, which varies among different tumor types and
subtypes, with median tumor mutation load deviating from
more than 10 somatic mutations per megabase in melanoma
to less than 0.1 in pilocytic astrocytoma. Highly mutated
tumors also include lung, esophagus, colorectum and blad-
der cancer, among others, while less-mutated tumors are
mostly represented by leukemias and thyroid cancer (14).
Even within a cancer type, this landscape can vary drasti-
cally since carcinogen exposure and specific mutations can
drag the mutation burden up or down (15). The neoantigen
load usually follows the mutation burden, with highly mutated
tumors displaying higher neoantigen load. Interestingly,
a study evaluating several tumors attributed a greater
role of frameshift mutations in producing strong binder
neoantigens than missense variants (16,17).
Although the oncology field is focused on seeking recur-
rent oncogenic (driver) mutations, under the immunological
point of view, driver mutations account for a very small frac-
tion of what is recognized by the adaptive immune system.
For instance, more than 90% of neoantigens recognized by
CD8+ T cells and virtually 100% of neoantigens recognized
by CD4+ cells are derived from passenger mutations (5).
This fact limits the possibility of a universal therapy for all
patients based on collections of mutated peptides since neo-
antigen collections are largely patientspecific. Neoantigens
derived from aberrantly expressed proteins (such as CEA
proteins and others) tend to display a more consistent pat-
tern of expression among different tumors, representing a
more likely collection of peptides for vaccination, although
these neoantigens are assumed to be less immunogenic than
those derived from mutated proteins (16,17). Advances in
personalized immunotherapy to accurately analyze the
patient’s neoantigen landscape are probably required for
further progress in ultra-personalized immunotherapy (5),
and different tumors respond better to different immune
interventions, as depicted in Figure 2. For highly immuno-
genic tumors, approaches that selectively enhance T cell
reactivity against this class of antigens are good strategies
to boost the recognition of tumors by immune cells.
The origin of high mutation burden
One of the main causes of the high mutation burden found
in some tumors is the mismatch repair deficiency caused by
either loss-of-function mutations present in the genes related
Figure 2 - General landscape of immunotherapeutic strategies for cancer treatment. Mutation burden among The Cancer Human
Genome Atlas (TCGA) samples can vary abruptly according to tumor type. This will restrict, at least in part, the immunological approaches
used for tumors. Each horizontal box represents a therapeutic strategy for which Food and Drug Administration (FDA) approval has
been granted and drugs available are available (solid squares). Compounds with strong evidence of clinical benefit are also depicted
(hatched squares). Some experimental therapies have already accumulated evidence suggesting that the therapy may be successful (double
hatched squares). Data sources: www.fda.gov, www.clinicaltrials.gov and reviewed bibliography. Adapted from (4,5).
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to this process or lower expression levels of some of these
genes derived from epigenetic alterations (18,19). Mutations
in mismatch repair machinery and POLE polymerase are
well reported for many tumors and are associated with
higher mutation burden in hypermutated colorectal cancer
and non-small cell lung cancer (20,21). In lung cancer, it is
well established that tobacco consumption is associated with
the presence of reactive oxygen species (ROS) which mainly
generates 8-hydroxy-2-deoxyguanosine, among other types
of damage. A specific repair mechanism led by 8-oxoguanine
DNA N-glycosylase (OGG1) mitigates this type of damage.
Park et al reported an improved risk of lung cancer in the
presence of polymorphisms in the OGG1 gene (22,23). It was
recently reported that a melanoma subset bearing a high
mutation burden was related to a loss-of-function mutation
in the ATR gene. The ATR protein senses mutations induced
by UV light and initiate cell cycle arrest through its down-
stream partner Chk1 along with the initiation of DNA repair (24).
There may be other mutations in DNA repair genes, such as
ATM and CHEK2, aside from the well-established mismatch
repair machinery, that are also responsible for a hypermutated
phenotype (25).
Neoantigen determination
Neoantigens can be generated by coding change muta-
tions, such as nonsynonymous single nucleotide variants
(nsSNVs) and (non) frameshift insertion or deletion events
(INDELs). Coding change mutations account for an average
of almost 2/3 of every somatic exonic mutation (26). A frame-
shift has the capacity to generate an entire new peptide
downstream from the mutation, increasing the chances of
neoantigen formation compared with nsSNV. Nevertheless,
the proportion of INDELs varies more than 10 times among
different tumors so that neoantigen generation by frameshift
mutations could be more frequent in some tumor types, such
as lung adenocarcinoma and renal cancer (16,17).
The cancer neoantigen determination pipeline can be
divided into three main steps: 1-Coding mutation identifi-
cation; 2-HLA typing of each sample; and 3-prediction of
peptide-HLA class I and II binding (Figure 3).
For the first step, high-confidence mutations in coding
sequences are identified from tumor sample sequencing data.
For neoantigen identification, only coding change muta-
tions are processed. In this sense, exome sequencing, which
focuses only on the 1% of the genome that comprises the
coding exons of known genes, is more suitable than whole-
genome sequencing. Mutation calling from sequencing data
is achieved by aligning sequence reads to a reference genome.
Once reads are aligned to the genome, variants are identified
including single nucleotide variants (SNV) and INDELs.
To better discriminate tumor-unique somatic mutations from
germline mutations and polymorphisms, sequencing of the
matched nontumoral sample is recommended for compar-
ison. Numerous calling algorithms have been developed,
handling both germline and somatic variants, or designed for
calling somatic mutations using tumor and matched normal
genomic sequences (27). After SNV and INDEL detection,
variants are annotated in coding and noncoding regions
genome-wide, and their functional impacts are predicted.
Only nonsynonymous mutations are used in the next step
to predict mutated peptide sequence affinities for the class I
HLA alleles of the same patient (28).
In the second step, HLA alleles from each patient are
determined. HLAs are remarkably polymorphic: there are
Figure 3 - Bioinformatics analysis of high-throughput data and its implications for cancer treatment. High-throughput platforms and
next-generation sequencing platforms have generated large amounts of data and consists of a rich source of information for cancer
research. Different techniques (top squares) are submitted to distinct pipelines, producing particular results (middle squares) that can
have unique implications for cancer therapy and research (bottom squares). For instance, from microarray data (red), the immune
landscape, the TAAs and immune checkpoint expression can be accessed, but neoantigens cannot be predicted. Joining multiple data
sources increases the level of information about the tumor and its microenvironment. Whole-genome sequencing (WGS), whole-exome
sequencing (WES), human leukocyte antigen (HLA), tumor-associated antigen (TAA), adoptive cell transfer (ACT), immune checkpoint
blockade (ICB), T cell receptor (TCR), B cell receptor (BCR).
4
Cancer immunotherapy approaches
Barros L et al.
CLINICS 2018;73(suppl 1):e429s
nearly 12 thousand class I HLA allelic sequences and 4.6
thousand class II HLA allelic sequences, which makes HLA
typing of each sample challenging (IMGT, 2017). The correct
allele determination is important for more precise peptide
binding affinity prediction. Software for HLA typing has
improved considerably in the last years, with heuristics that
identify class I major alleles with an accuracy of 97%. In one
of the main methods, reads are mapped against constructed
HLA I allele references using representative exons instead
of the full sequence. New algorithms are emerging that
consider the entire locus sequence and are capable of more
precise typing of both class I and II alleles (29-31).
In the third step, in silico prediction of peptide binding
strength to patient-specific HLA alleles uses algorithms based
on neural network-based learning approaches that have
been developed using large amounts of data describing
peptides that bind with different strengths to a wide variety of
class I HLA molecules (32). The methods of peptide:HLA
complex (pHLA) prediction are mainly based on viral and
bacterial-derived peptides presented by class I HLA mole-
cules (32), possibly adding a bias in near-self derived pHLA
prediction. A fraction of HLA I-bound peptides was recently
reported to be a product of peptide splicing, which adds another
level of complexity to neoantigen determination, not accounted
for in the in silico predictions (33). Accurate peptide binding
prediction is more difficult for class II HLAs than for class I
HLAs, as class II HLA molecules are open on both ends, allow-
ing different peptide accommodations. Even with the constant
improvements in prediction software, the precise peptide core
identification for HLA-II binding remains challenging (31).
In addition to affinity, pHLA binding is also influenced
by epitope abundance and antigen processing (i.e., protein
degradation and peptide transport). Therefore, epitope abun-
dance is currently estimated indirectly by quantitating mRNA
expression levels. However, a concern of neoantigen pre-
diction not frequently discussed is that mRNA levels
do not strictly correlate with protein levels (32), since the
kinetics of mRNA translation and protein degradation are
regulated by distinct steps. While RNA concentration can
be measured by RNA-seq or quantitative PCR, the protein
concentration matters both for cell function and peptide
binding to HLA molecules. This is critical for neoantigen
prediction because the majority of pHLA is composed of
the highest expressed mRNA, while low expressed mRNAs
are less represented (32). For the proposal of neoantigen can-
didates for immunotherapy, one should take into account
not only the predicted pHLA affinity measured by in silico
analysis but also the mRNA expression to increase the chance
of identifying better candidates. Another issue to take into
account is the intratumoral neoantigen distribution, where
some tumor cells share common neoantigens. Targeting clonal
neoantigens instead of private neoantigens (those expressed
exclusively by subclonal populations) could lead to better
clinical responses (34). While the neoantigens derived from
mutations are unique to almost all patients (less than 5%
overlap among patients), TAA-derived peptides are often
shared among patients and cancer types and are suitable for
general cancer vaccines, as we discuss further in this review.
Tumor microenvironment deconvolution and
immune circuit characterization
The interplay of tumor and microenvironment components
is now largely recognized as one of the pillars for tumor
progression and dissemination (35). We now know that immune
components of the tumor microenvironment can impact the
prognosis of tumors and their response to chemotherapy in a
certain tumor, such as colorectal cancers (36,37). This informa-
tion points to the relevance of accurately describing the immune
components of the tumor microenvironment. Some initia-
tives in this sense have been developed based on the immuno-
histological characterization of cell populations in the tumor
(37). For instance, the Immunoscore initiative was conceived to
evaluate the number, type and location of immune infiltrates in
primary tumors and has been used as a prognostic factor for
disease-free survival and overall survival (37).
Taking advantage of the new sequencing platforms
and the availability tumor data from thousands of patients,
especially from The Cancer Genome Atlas (TCGA) project,
several tools have been developed to evaluate the immune
cell population within tumors based on microarray and NGS
expression data. Although exciting, this huge amount of data
is challenging to analyze. Computational approaches capable
of discerning and quantitating the individual immune cell
type profiles from their bulk mixture using expression profiles
have been developed to analyze the subsets of immune cells
present in a tumor sample. These deconvolutionmethods rely on
an expression signature matrix for individual cell populations
and account for tumor-to-tumor variability, intratumoral hetero-
geneity, and the relatively low fraction of immune cells (28). One
of these tools is the CIBERSORT. It estimates the relative contri-
bution of 22 different immune cell types of a mixture sample
from both microarray and RNA-seq data by applying a machine
learning support vector regression approach to perform feature
selection, in which genes from the signature matrix are adapti-
vely selected to deconvolve the mixture (38). In a recent work,
by applying CIBERSORT to thousands of tumor samples from
TCGA and other public data banks and including every immune
cell population in survival analyses, considerable variations
among immune populations were observed to be cancer-specific,
with many statistically significant associations. The authors also
showed that some T cell population (CD8+ T cells) signatures
always correlate with a greater overall survival, while myeloid
populations are primarily correlated with poorer survival (39).
Immune cell populations (27 immune cell subtypes based
on gene-set enrichment analysis (GSEA)) and inhibitory, stim-
ulatory and MHC molecules can be evaluated from RNA-seq
data and integrated by the immunophenoscore (IPS) algo-
rithm. This algorithm was developed by machine learning
using a random forest classification approach, which was
based on multitude decision trees, including 127 parameters.
The IPS profile differs between melanoma patients who
respond or do not respond to immune checkpoint blockade
(ICB) therapy (for anti-PD-1 and anti-CTLA-4), posing clear
potential implications of this algorithm as a response predictor
tool to immunotherapy (40).
Immunotherapeutic strategies and their relationship
with immunological aspects of the tumors
In the last two decades, several reports showing that
T lymphocytes can recognize tumor antigens and shape the
evolution of the disease have led to an improved under-
standing of the relationship between the immune system and
tumors. This has culminated in the development of immuno-
therapies aimed to generate or enhance antitumor T cell
responses by using vaccines, blocking antibodies, and adop-
tive cell transfer of genetically modified T lymphocytes.
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These immunotherapeutic approaches are revolutionizing
the treatment of different types of cancer, inducing long-
term clinical benefits in patients who were resistant to
conventional therapies.
Immune checkpoint blockade
The increasing knowledge on the process of triggering and
supporting an immune response has led to the identifica-
tion of several molecules capable of regulating the immune
response. Among these molecules are the so-called immune
checkpoint inhibitors, which include CTLA-4, PD-1, LAG-3
and others. These molecules can be efficiently targeted by
ICB using monoclonal antibodies, such as those blocking
CTLA-4, PD-1 or its ligand PD-L1 (41). An extensive descri-
ption of the remarkable results obtained with ICBs is beyond
the scope of this review, and we refer the reader to the
excellent reviews addressing this topic (42,43).
In 2010, a randomized phase 3 trial showed that the CTLA-4
antibody (ipilimumab) improves the overall survival in patients
with metastatic melanoma (44), which led to the first drug
for checkpoint blockade approved by the Food and Drug
Administration (FDA) in 2011. Anti-PD-1 and anti-PD-L1
were soon after approved for metastatic melanoma treat-
ment, and recently, the anti-PD-L1 mAb atezolizumab was
approved for treatment of urothelial carcinoma, and pembro-
lizumab (PD-1), for non-small cell lung cancer (NSCLC).
Combination therapies blocking CTLA-4 and PD-1 have been
tested, and results have shown improved overall survival
compared with monotherapy in patients with advanced mela-
noma (45) and metastatic renal cell carcinoma (46). Due to these
promising results, new target molecules (LAG-3, TIM-3, B7-H3,
etc.) are under study, and we foresee several combinations of
ICBs and inhibitors of other immunomodulatory molecules,
such as indoleamine-2,3-dioxygenase (IDO), tryptophan-2,
3-dioxygenase (TDO) or arginase. The combination of mono-
clonal antibodies agonistic to costimulating receptors in
T lymphocytes, such as OX-40, CD28 or 4-1BB, could also
be evaluated to further stimulate T cells (47,48).
Several aspects of the response to ICB can be addressed by
characterizing the tumor in terms of immune response and
mutation-related antigenic load. Hypermutated tumors are
capable of generating great amounts of neoantigens and may
respond better to ICB (Figure 2). Despite the absence of a
precise biomarker of the immune checkpoint blockade
response, elevated mutation load was shown to be a related
factor in the CTLA-4 blockade response in melanoma (49). In
addition to the mutation and neoantigen load, mismatch
repair deficiency, CD8+ T cell infiltrate and genomic insta-
bility have also been associated with good prognosis in
patients treated with ICBs (50,51). One of the ICBs for PD-1
was recently approved for therapy in tumors bearing mis-
match repair deficiency as the sole criterion for clinical
indication, independent of the anatomical site of the tumor,
representing a new paradigm for cancer treatment.
Together, these data suggest a multifactorial scope that
should be taken into account to better predict the patient’s
response to these target therapies (25).
Predicting ICB responses in tumors can be challenging
although extremely relevant considering the high economic
costs of this therapeutic modality. Several initiatives are
focusing on the development and implementation of refined
algorithms, such as the IPS already mentioned, that can reliably
predict responses in tumors. A different approach is evaluating
response profiles soon after ICB administration. The aim of this
approach is to identify dynamic response markers in the tumor
microenvironment or in peripheral blood. Recent reports using
mass cytometry highlight some lymphocyte cell populations
associated with ICB response patterns in mouse models (52,53)
and in patients for CTLA-4 and/or PD-1 blockade (54).
Oncolytic viruses as therapeutic tools
In 2015, the United States, Europe and Australia approved
an oncolytic virus immunotherapy for the treatment of
advanced melanoma. The approved oncolytic virus is a herpes
simplex virus type 1 (HSV-1) engineered to express the
human granulocyte-macrophage colony-stimulating factor
(GM-CSF), called Talimogene laherparepvec (T-vec). Tumor
regression can be achieved by infecting and directly killing
the highly proliferating malignant cells. The dying tumor
cells can expose more antigens and prime several T cells,
generating a systemic tumor-specific immune response (55).
The insertion and expression of GM-CSF in the cell by the
virus also leads to dendritic cell and macrophage recruitment
and maturation within the tumor, which makes this therapy
suitable for tumors without an important immune cell infil-
trate (56). The virus proteins themselves elicit an immune
response within the tumor, causing more homing of immune
cells. Unfortunately, the immune response triggered by the
virus itself induces an adverse effect in some patients, most
notably in herpes seronegative patients injected with high
viral doses. The side effects included local inflammation,
erythema and febrile response, which could be managed by
multidosing therapy: administer patients a low dose of virus
for seroconversion and then administer a high dose (57).
A randomized phase III clinical trial with metastatic mela-
noma patients showed that T-vec reduced the injected lesions,
uninjected nonvisceral lesions and uninjected visceral lesions,
validating the therapy as a systemic immunotherapeutic
approach. Overall, 48% of patients had progression prior to
response, and no difference in the overall survival had been
observed until receiving this treatment (58).
Recently, a phase Ib clinical trial showed promising results
in advanced melanoma patients combining ICB and T-Vec.
The patients received the anti-PD-1 antibody pembrolizumab
and multiple doses of T-vec. Although it was not possible to
evaluate the median progression-free survival and overall sur-
vival, 62% of patients had an objective response, and 33% of the
patients experienced a complete response of lesions (21,59-61).
Antigen-based tumor vaccines
Inspired by the success of vaccines in infectious diseases,
experimental vaccines were developed against different tumor
antigens with the objective of inducing an endogenous res-
ponse against the tumor. The first vaccines tested were TAA
peptides (62), because they are expressed by several patients
and different types of tumors. However, despite years of
research and development, the only cancer vaccine approved
by the FDA to date is sipuleucel-T (Provenge) for the treat-
ment of metastatic prostate cancer. This vaccine consists of
autologous blood monocytes loaded with a prostate cancer
antigen (prostatic acid phosphatase [PAP]) fused to GM-CSF,
leading to a modest survival benefit of only 4.1 months (63).
Additional reports in the literature showed that vaccinations
against MAGE-A3 (64) and NY-ESO-1 (65) peptides/protein
can induce a T cell response in patients, but these are not
sufficient to promote tumor regression.
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The limited success of these vaccines is potentially related
to the choice of target antigens, which focus on TAAs. While
a vaccine targeting TAAs would benefit all patients who
express the selected antigen(s), the T cell clones that respond to
them probably express low affinity T cell receptors (TCRs) or
were tolerized by central and peripheral tolerance mechanisms.
The high-throughput discovery of neoantigens allow the design
of cancer vaccines targeting unique tumor antigens expres-
sed by tumors (especially for those hypermutated). It has been
proposed that an ideal neoantigen-based vaccine for cancer
therapy should be composed of at least 20 epitopes in peptides
greater than 20 amino acids long to favor cross-presentation
and should include many neoantigens, thus preventing a
reduction in immune system pressure by antigen loss by tumor
mutations and enhancing immunological responses (17).
Two recent reports described the use of a personalized
vaccine based on neoantigens identified in each patient to
treat melanoma. In one of them, long peptides harboring the
neoantigen sequence were synthesized, considering multiple
cuts for each amino acid-altered sequence to represent the
neoantigen. Four peptide pools, totaling up to 20 peptides
per patient, were administered in a series of five priming
vaccine administrations to patients followed by two boosting
steps. Approximately 25 months after vaccination, 4 of the
6 patients exhibited sustained remission with no sign of disease
recurrence. The two remaining patients were subjected to anti-
PD1 ICB therapy and thus achieved remission after a few
months. These results indicate the potential of ICB in unleashing
the antitumor potential of suppressed T cell responses (60).
The other study used an RNAvaccine with ten neo-peptides,
exclusive for each patient, encoded in two molecules. The
peptides were selected based on HLA-I and HLA-II bind-
ing affinity and on the expression of the mutated target.
A maximum of 20 doses in a continuous treatment paradigm
were administered without serious adverse events, and some
patients generated a strong immune response. Complete res-
ponses were achieved in one patient after combination with
anti-PD-1 and in another previously submitted to CTLA-4
blockade. One patient had a lymph node metastasis that
stabilized after vaccination. The last patient was apparently
tumor-free after the therapy, but died due to fast tumor
progression. Further investigations revealed an acquired beta-2-
microglobulin (B2M) deletion on both alleles, in line with its
role in proper MHC class I antigen presentation. There was a
response against 60% of predicted neo-peptides, of which the
majority were recognized by CD4 cells, and 29% of predicted
class I neo-epitopes generated a CD8+ T cell response. This
study suggests that vaccination using poly-neo-epitopes seems
an effective way to prevent escaping clones and recurrent
disease (61). Together these data demonstrate the power
and feasibility of neo-antigen-based vaccines. However, some
challenges persist. For example, refinements are still needed to
improve the accuracy of in silico prediction of neo-antigen
immunity. The time feasibility, ideal administrations and costs
of such approaches should also be further evaluated (5,17).
Despite the promising results obtained with neoantigens
vaccines, this approach requires efficient in vivo priming
and clonal expansion of antitumor T lymphocytes, steps that
are often inhibited by the immunosuppressive environment
induced by the tumor. Moreover, the T cell clones responsive
against neoantigens might be inhibited by peripheral tolerance
mechanisms, such as PD-1-mediated signaling. This opens the
possibility of combining some of the kill and boost therapies for
tumors (such as peptide-based vaccines or oncolytic viruses) to
ICB in order to potentiate the engagement of the immune
system by unleashing its potential while avoiding inhibitory
signaling circuits to promote antitumor effects.
T cell-based therapies
In addition to cancer vaccines and ICBs, cellular therapies
that also exploit the endogenous responses against tumor
cells were developed, mainly for melanomas. One approach
derived from the observation that, in melanoma patients,
a subset of T lymphocytes migrates and recognizes the tumor.
These T lymphocytes are called tumor infiltrating lymphocytes
(TILs), and protocols have been developed to isolate and
expand these cells in vitro (66,67). The adoptive transfer of these
cells achieved clinical responses in a significant proportion of
metastatic melanoma patients, with robust results not pre-
viously observed with chemotherapy-based treatments (68).
Most tumors lack abundant TILs or even the capacity to
generate efficient T cell responses on their own, even if TAAs
(or neoantigens) are expressed by the transformed cells.
In the absence the stimulation of previous T cell responses,
additional strategies can be developed to generate artificial
T cell responses against the tumor.
Previous studies have described TAAs that are expressed
in a high proportion of cancer patients; these include MART-1
and gp100 in patients with melanoma and several cancer/
testis antigens and NY-ESO-1 and MAGE-A3 expressed in a
variety of cancer types (69). Several groups have cloned and
described the T cell receptors (TCRs) that recognize these
antigens, showing that T cells transgenically modified to
express these antitumor TCRs can recognize and eliminate
cancer cells in vitro and in vivo. These TCR-modified T cells
were used in clinical trials for treatment of distinct types of
cancer, such as sarcomas and melanomas, and induced
significant clinical responses in patients (70-72). These trials
also revealed that TCR-based immunotherapies can be asso-
ciated with off-target responses, as evidenced by the recogni-
tion of titin (73) and MAGE-A12 (74) by T cells engineered to
recognize MAGE-A3. The resulting toxicity culminated in the
death of 5 patients in these clinical studies, highlighting
the need of better in vitro and in vivo methods to evaluate the
activity of TCR-engineered lymphocytes to avoid on-target/
off-tumor side effects.
Bioinformatics-based neoantigen determination pipelines
allow a broader use of this approach, extended to cancers
without described TAAs. This personalized approach involves
the analysis of tumor DNA or RNA sequences for the
identification of neoantigens (75,76) combined with the
identification of T cell clones that respond to these antigens.
Recent reports show that the infusion of T cell clones against
neoantigens can induce tumor regression in patients with
cholangiocarcinoma (77) and colorectal cancer (78). It is impor-
tant to note that CD8+ Tcells frommatched HLA donors were
shown to recognize additional tumor neoantigens compared
with autologous lymphocytes, which could potentially be a
complementary source of reactive T cell clones or TCRs for
patients who lack a natural appropriate immune response
against the tumor (79).
Chimeric antigen receptor (CAR)-based therapies
The immunotherapeutic approaches discussed so far require
a pre-existent immune response against tumor neoanti-
gens, which is more likely to occur in tumors characterized
by high mutational load. Tumors with low mutation burden,
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e.g., leukemias, lymphomas and thyroid cancer, are less
likely to generate neoantigens due to their low mutation
burden. Even frequently mutated tumors, with a consider-
able number of neoantigens, sometimes do not respond
well to neoantigen vaccines (80). The use of chimeric anti-
gen receptor (CAR)-based immunotherapy in this setting
has the potential to induce an immune response against
tumor cells by redirecting T cell activity towards the tumor.
CARs are composed of an scFv derived from an antibody as
an extracellular domain, a transmembrane domain and an
intracellular domain derived from key signaling proteins of
the TCR pathway (81). CAR genes are normally transferred
to T cells by a DNA-integrating vector, such as a retrovirus,
a lentivirus or transposons (82). CAR-expressing T lympho-
cytes can recognize a TAA of peptidic, glycidic or even
lipidic nature on the surface of the target cells, activating
the T cells and inducing their effector functions. This design
bypasses the interaction with the HLA/peptide complex,
allowing T cells to kill all target tumor cells, including the
ones downregulating HLA and, thus, avoiding an important
mechanism of tumor evasion. Furthermore, the addition of
costimulatory domains such as CD28 or 4-1BB to CARs
(second generation CARs) increases the effector function and
prolongs in vivo persistence of T cells, which has shown
substantial efficacy in several preclinical tumor models (83).
Second-generation CARs targeting CD19 were the first to
induce significant clinical benefit for patients, being used
for the treatment of B cell malignancies (84-85). Subsequent
trials showed remarkably high complete response rates in
these patients (86), which laid the foundation for the FDA
approval of CAR T cell therapy for the treatment of pediatric
B cell leukemia (commercialized by Novartis) and B cell
lymphoma (commercialized by Kite Pharma/Gilead), the
first gene therapies approved in the USA.
However, the use of CAR lymphocytes for the treatment of
solid tumors has not induced the same type of dramatic
response as seen in B cell leukemias/lymphomas. The asso-
ciated microenvironment established during tumor progres-
sion has a potential role in inhibiting CAR T cell migration
and activity. Indeed, preclinical studies have shown that
cytokines, such as IL-4 (87) or the tryptophan metabolizing
enzyme IDO (88), can inhibit the function of CAR T cells
inside the tumor microenvironment. Furthermore, inhibitory
ligands expressed by immune cells and/or tumor cells in the
tumor microenvironment, such as PD-L1 and PD-L2, also
contribute to decreasing T cell function, and genetic engi-
neering these T cells to become resistant to these signals
improves T cell activity in vivo (89). The combination of CAR
T cells with PD-1/PD-L1 blocking antibodies is being tested
in several clinical trials, with one report showing promising
results in a patient with B cell lymphoma (90). However,
a recent published trial in which neuroblastoma patients were
treated with anti-GD2 CARs in combination with lympho-
depletion and PD-1 blockade showed no improvement in
Tcell function in vivo (91). CAR therapies also carry an intrinsic
risk of promoting on-target off-tumor adverse effects. One
patient was reported to have a fatal off-tumor effect due to
pulmonary responses of a 3rd generation CAR specific for the
erbb2 antigen (92). This risk is being addressed by designing
safety switches for CAR constructs such as the CD20 (93),
iCaspase9 (94), and HSV-TK (95) suicide genes or inducible CAR
systems based on synthetic inducers (96). Fine tuning of CAR
functions can also be achieved by selecting proper CAR affinities
(97,98) using combinations of CARs targeting different antigens
(99,100) or logic gate approaches for conditioning CAR activities
to input signals (101) to improve its safety profile (81,102).
Next steps
Cancer immunotherapy has evolved from a long-lasting
promise to an exciting reality in the last decade. Our current
rudimentary knowledge about the immune mechanisms
underlying antitumor immune responses and tumor bio-
logy suggests that much higher tumor response rates will
be achieved once we gain a deeper knowledge of tumor-
immune system interactions. We anticipate the development
of both immune characterization tools for the tumor micro-
environment and response markers that will allow us to
choose the best immunotherapy for each patient instead of
using the current ‘‘one treatment for all’’ approach. Combin-
ing immunotherapy modalities will also play a major role in
next-generation immune-based therapeutic approaches, and
we are currently witnessing only the beginning of this era.
After more than a century of unmet immunotherapy
expectations, we can finally see decades of basic studies that
described the operational mechanisms of the immune system
setting the basis for the first generation of successful immuno-
therapies. The groundwork has been laid for the next
generation of immune-based anticancer therapies.
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